BTIG analyst Dane Leone weighed in on Regeneron Pharma (NASDAQ: REGN), saying the Repatha Outcomes Data Reinforces our Model Forecast ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE